NASDAQ: PYXSPyxis Oncology Inc Stock
$3.56+0.14 (+4.09%)
Updated Oct 31, 2025
PYXS Price
$3.56
Fair Value Price
$2.06
Market Cap
$220.78M
52 Week Low
$0.83
52 Week High
$5.39
P/E
-2.24x
P/B
2.52x
P/S
24.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.82M
Earnings
-$96.29M
Gross Margin
100%
Operating Margin
-3,481.1%
Profit Margin
-3,414.4%
Debt to Equity
0.41
Operating Cash Flow
-$74M
Beta
1.08
Next Earnings
Nov 18, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PYXS Overview
Pyxis Oncology, Inc. is a preclinical stage biopharmaceutical company developing cancers therapies. Its product candidate, PYX-106, targets thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. PYX-102 is an investigational immune-therapeutic for treatment of solid tumors. Pyxis Oncology was incorporated in 2018 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PYXS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PYXS
Ranked#152 of 488
Ranked#152 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important PYXS news, forecast changes, insider trades & much more!
PYXS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PYXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PYXS ($3.56) is overvalued by 73.22% relative to our estimate of its Fair Value price of $2.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PYXS ($3.56) is not significantly undervalued (73.22%) relative to our estimate of its Fair Value price of $2.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PYXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PYXS due diligence checks available for Premium users.
Valuation
PYXS fair value
Fair Value of PYXS stock based on Discounted Cash Flow (DCF)
Price
$3.56
Fair Value
$2.06
Overvalued by
73.22%
PYXS ($3.56) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PYXS ($3.56) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PYXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PYXS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.24x
Industry
-9.17x
Market
41.65x
PYXS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.52x
Industry
4.99x
PYXS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PYXS's financial health
Profit margin
Revenue
$2.8M
Net Income
-$18.4M
Profit Margin
-650.9%
PYXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PYXS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$123.2M
Liabilities
$35.6M
Debt to equity
0.41
PYXS's short-term assets ($99.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PYXS's short-term assets ($99.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PYXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.3M
Investing
$15.3M
Financing
-$67.0k
PYXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PYXS vs Biotech Stocks
Pyxis Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.